Short answer
Biogen (BIIB) filed its Q3 2025 10-Q quarterly report on Oct 30, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $2.5B (up 2.8% year over year) with net income of $467M.
Q3 2025 key financials · XBRL
- Revenue
- $2.5B
- +2.8% YoY · −4.2% QoQ
- Net income
- $467M
- +20.1% YoY · −26.5% QoQ
- EPS (diluted)
- $3.17
- +19.6% YoY · −26.8% QoQ
Source: XBRL data from the Biogen (BIIB) Q3 2025 10-Q on SEC EDGAR. USD.
Biogen Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $2.535B for Q3 2025, up $68.9M (2.8%) YoY from $2.466B in Q3 2024
- Operating margin approx. 21.7% in Q3 2025 ($557.3M income before tax on $2.535B revenue) vs 18.3% in Q3 2024 ($451.0M on $2.466B)
- Best segment: Multiple Sclerosis product revenue grew to $1.0615B in Q3 2025 vs $1.0539B prior year; rare diseases segment revenue $533.3M vs $494.8M
- Worst segment: Contract manufacturing, royalty and other revenue declined to $151.2M in Q3 2025 from $231.6M in Q3 2024
- Cash and equivalents increased to $3.863B at Sept 30, 2025 from $2.375B at Dec 31, 2024; operating cash flow $1.693B for first nine months 2025 vs $2.115B prior-year period
- Management notes continued profitability driven by multiple sclerosis and rare disease products, increased Alzheimer's collaboration revenue; ongoing restructuring and acquisitions incur expenses but expected to enable future growth
- Near-term outlook cautious with acknowledgement of competitive, regulatory, and legal risks; no updated revenue guidance disclosed; focus on pipeline advancement and global commercial strategies
Risk Factors
- New risk: Generic TECFIDERA competition started in North America, Brazil, Europe triggering revenue decline and ongoing patent litigation in Europe through 2028
- Most updated risk: Impact of Inflation Reduction Act (IRA) Medicare Part D redesign expected to reduce 2025 revenue by $50-100M, mainly on SKYCLARYS and MS portfolio
- Regulatory risk: OBBBA law signed July 2025 alters Medicaid funding and ACA subsidies; full impact on business remains uncertain pending further regulations
- Operational risk: Supply chain disruptions risk from geopolitical tensions, tariffs, raw material shortages, plus reliance on international manufacturing for key products (TECFIDERA, LEQEMBI)
- Financial risk: Liquidity strengthened to $4.0B cash and equivalents as of Sept 30, 2025; raised $1.75B via 2025 Senior Notes to redeem notes due Sept 2025, maintaining debt at $6.3B
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Biogen quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.